Virion Therapeutics Reports Progress Towards HBV Functional Cure with Sustained and Continued HBsAg Declines up to One Year After a Single VRON-0200 Dose From its Phase 1b Study at AASLD’s The Liver Meeting® 2025
Virion Therapeutics, LLC, a clinical-stage biotechnology company, developing novel T cell-based immunotherapies that utilize checkpoint modifiers, today announced at AASLD’s The Liver Meeting®, in Washington DC, that a single intramuscular dose of VRON-0200, its novel, first-in-class, immunotherapy for HBV Functional Cure, induced HBV-specific immune activation, restoration, and HBsAg declines, that were sustained and/or continued up to one-year post dosing, in the majority of chronically HBV-infected treated patients. The data, presented as an oral presentation, by Dr. Grace Wong, M.D., from the Chinese University of Hong Kong, also highlighted VRON-0200’s ongoing favorable safety and tolerability profile, and rapid and profound HBsAg declines when VRON-0200 was combined with an investigational antiviral regimen.
Virion Therapeutics Announces Upcoming Clinical Presentation Highlighting VRON-0200 Study Progress Towards Achieving HBV Functional Cure at AASLD's The Liver Meeting® 2025
Virion Therapeutics, LLC, a clinical stage biotechnology company, developing novel T cell-based immunotherapies that utilize checkpoint modifiers, today announced that an abstract highlighting key new clinical data from its VRON-0200 Chronic Hepatitis B virus (HBV) program, has been accepted for oral presentation at the upcoming American Association for the Study of Liver Diseases (AASLD), The Liver Meeting®, in Washington, DC, November 7-10, 2025. In addition, Virion announced an abstract highlighting manufacturing enhancements, developed for its platform technologies and used for the VRON-0200 program, has been accepted for oral presentation at the upcoming Vaccines Summit in Boston, MA, November 13-15, 2025.
